TrialCancer immunology, immunotherapy : CII2006

Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.

A N Alexander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.